Hot off the press- The U.S. Food and Drug Administration (FDA) has approved Sanofi-Aventis SA’s new
chemotherapy drug for advanced prostate cancer.
The drug, Jevtana (cabazitaxe) extended by nearly 2-1/2 months the lives of men with prostate
cancer tumors that resist standard treatment with hormones as well as chemotherapy.
The drug will be used after taxotere has failed.
Read more about this drug on my March 5, 2010 post, “On The Horizon – Cabazitaxel Extends Life After Chemotherapy Failure.”
Another break for men with advanced prostate cancer. Cabazitaxel, no longer “on the horizon”, it is now here today!
Joel T Nowak, MA, MSW
What am I missing here?
One’s life is extended by 2 1/2 months, and that’s reason for joy?
Just the other day, you posted how futile the interventions really are in extending life for any meaningful pd of time.
And, how little progress has been made over these many years.
Yet, I do appreciate greatly your provinding this information.
Hooray for the FDA! This is the swift action that patients with advanced cancer need.We need them to maintain this pace.